Dividends, Drug Trends Report, Upcoming Financial Results, Earnings Results, and Superior Proposal Receipt - Analyst Notes on Walgreens, CVS Caremark, Rite Aid, Cardinal Health, and Chindex

NEW YORK, April 22, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Walgreen Co. (NYSE: WAG), CVS Caremark Corporation (NYSE: CVS), Rite Aid Corp. (NYSE: RAD), Cardinal Health, Inc. (NYSE: CAH), and Chindex International Inc. (NASDAQ: CHDX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

--

Walgreen Co. Analyst Notes 

On April 9, 2014, Walgreen Co. (Walgreens) announced that its board has declared a regular quarterly dividend of $31.5 per share, a 14% increase since last year's dividend. According to the Company, the dividend is payable on June 12, 2014 to shareholders of record as of May 21, 2014. The full analyst notes on Walgreen Co. are available to download free of charge at:

http://www.AnalystsReview.com/04222014/WAG/report.pdf

--

CVS Caremark Corporation Analyst Notes 

On April 10, 2014, CVS Caremark Corporation's (CVS Caremark) Insights report cited a 3.8% increase in prescription drug spending in 2013, compared with 0.1% growth in 2012. The Company stated that in traditional medications, the trend is a far cry compared with the prescription drug, having only registered 0.8% growth in 2013, a slight increase from the 3.8% decline in 2012. According to the Company, this resulted from the increased demand for specialty drugs treating complex diseases, which grew by 15.6% in 2013. Jon Roberts, President, CVS Caremark's Pharmacy Benefit Management Business, said, "This year's Insights report outlines seven sure things that our clients should keep in mind. These include: prescription trend is up, generics have peaked, specialty drives trend, price is king, money matters to members, adherence is the answer and past performance is no guarantee of future results." The full analyst notes on CVS Caremark Corporation are available to download free of charge at:

http://www.AnalystsReview.com/04222014/CVS/report.pdf

--

Rite Aid Corp. Analyst Notes 

On April 10, 2014, Rite Aid Corp. (Rite Aid) reported its Q4 FY 2014 and full-year FY 2014 financial results (period ended March 1, 2014). Q4 2014 revenues increased to $6.6 billion, up 2.2% YoY, and annual revenues slightly increased to $25.5 billion, up 0.5% YoY. However, quarterly net income decreased to $55.4 million, or diluted EPS of $0.06, compared with $123.1 million, or diluted EPS of $0.13, in Q4 FY 2013. Meanwhile, annual net income increased $249.4 million, or diluted EPS of $0.23, compared with $118.1 million, or diluted EPS of $0.12, in full year 2013. John Standley, Ride Aid Chairman and CEO, noted that its recent acquisition of Health Dialog and RediClinic strategically positioned the Company in pursuing opportunities to becoming a growing retail healthcare company. "These accomplishments reflect the significant progress we're making in executing key initiatives and delivering on our promise to actively work with our customers to keep them well," Standley added. The full analyst notes on Rite Aid Corp. are available to download free of charge at:

http://www.AnalystsReview.com/04222014/RAD/report.pdf

--

Cardinal Health, Inc. Analyst Notes 

On April 10, 2014, Cardinal Health, Inc. (Cardinal Health) announced that it will release its Q3 FY 2014 financial results on May 1, 2014, before the opening of trading on the New York Stock Exchange. The Company informed that it will also broadcast the results via webcast and conference call that same day at 8:30 a.m. ET. Presentation slides will be archived on the Company's website, as well as the audio replay, which will only be available for seven days after the presentation. The full analyst notes on Cardinal Health, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04222014/CAH/report.pdf

--

Chindex International Inc. Analyst Notes 

On April 14, 2014, Chindex International Inc. (Chindex) announced its receipt of offer from a financial bidder to acquire all of the Company's outstanding common stock shares for $23 per share in cash. The Company's committee of independent directors advised the bidder to submit a superior proposal. In addition, the definitive terms and conditions for the merger agreement is subjected by execution of the Company, and is not subject to any financing condition that any existing stockholders of the Company participate in the merger by rolling over equity, or entering into a voting agreement. The full analyst notes on Chindex International Inc. are available to download free of charge at:

http://www.AnalystsReview.com/04222014/CHDX/report.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED